Skip to main content

Day: February 20, 2025

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth quarter revenue of $168 million and full year revenue of $634 million Fourth quarter orders and revenues sequentially increased 11% and 8% respectively Orders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenueWALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024. The company is also providing financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “During the fourth quarter, we were very encouraged by the continued momentum...

Continue reading

CoreCard Corporation Reports Fourth Quarter and Full Year 2024 Results

NORCROSS, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or “the Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter and full year ended December 31, 2024. “Overall revenue of $14.8 million in the fourth quarter was above our expectations due to unexpected license revenue in the quarter and in-line with our expectations excluding the license revenue. Services revenue during the quarter was in-line with our expectations, reflecting continued year-over-year growth in processing and maintenance revenue of 11%. Additionally, our full year processing and maintenance revenue grew by 7% compared to full year 2023,” said Leland Strange, CEO of CoreCard...

Continue reading

Laureate Education Reports Financial Results for the Fourth Quarter and Full-Year 2024 and Provides 2025 Outlook

MIAMI, Feb. 20, 2025 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the fourth quarter and the year ended December 31, 2024. Fourth Quarter 2024 Highlights (compared to fourth quarter 2023):On a reported basis, revenue increased 3% to $423.4 million. On an organic constant currency basis1, revenue increased by 10%. Operating income for the fourth quarter of 2024 was $124.2 million, compared to $110.0 million for the fourth quarter of 2023. Net income for the fourth quarter of 2024 was $93.6 million, compared to net income of $41.7 million for the fourth quarter of 2023. The increase in net income was mainly driven by the effect of changes in foreign currency exchange rates on intercompany balances compared...

Continue reading

Atos successfully deploys new, innovative sport technologies during the Winter European Youth Olympic Festival Bakuriani 2025

                                                                News Atos successfully deploys new, innovative sport technologies during the Winter European Youth Olympic Festival Bakuriani 2025 New, integrated technologies contributed to the event success and are now field-proven, ready to be deployed at a larger scale. Bakuriani, Georgia, and Paris, France, February 20, 2025 – Atos, a global leader in digital transformation and the Technology Partner of the Winter European Youth Olympic Festival (EYOF) Bakuriani 2025, today announces that its innovative IT services contributed to the success of the event from February 9 to 16, 2025. Atos delivered a comprehensive suite of digital services that enhanced fan experience, optimized event operations, and brought the Festival closer to audiences across Europe. Atos provided traditional...

Continue reading

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Media Release COPENHAGEN, Denmark; February 20, 2025Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who had received two or more lines of systemic therapy EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in Japan to treat both R/R FL and R/R large B-cell lymphomas, after two or more prior lines of therapy EPKINLY is the only bispecific antibody approved with a dual indication for the treatment of certain B-cell malignancies in the United States, European Union and JapanGenmab A/S (Nasdaq: GMAB) announced today that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY® (epcoritamab) for the treatment of patients with relapsed...

Continue reading

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

WHO WHAT WHERE WHEN WHYNuwellis, Inc., and Dr. Sean P. Pinney and Dr. Maria V. DeVita Updated analysis of the AVOID-HF study data shows that Aquadex® SmartFlow ultrafiltration therapy led to a 60% reduction in heart failure events compared to standard diuretic therapy. Journal of the American College of Cardiology Findings were recently updated and analyzed as of 2/19/25 These promising results support further research into ultrafiltration’s role in heart failure management and highlight its potential to improve treatment outcomes, supporting the current Nuwellis REVERSE-HF trial.MINNEAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today highlighted promising findings from an updated analysis...

Continue reading

UPSTACK Acquires IT Advisory Firm V3 Technology

Founder & President Tom VanVeckhoven Joins UPSTACK as Partner NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — UPSTACK, the leading full-service technology advisory firm, today announced the acquisition of Arkansas-based V3 Technology Inc., an IT advisory firm providing innovative technology strategies for midmarket businesses. As part of the deal, V3 Technology President Tom VanVeckhoven will join UPSTACK as a Partner. The V3 team, including Miles VanVeckhoven, V3’s Vice President of Sales and Operations, also will join UPSTACK. Founded in 2012, V3 Technology is a powerful group of telecom and IT veterans with more than 70 years of combined experience working with service providers to help customers maximize the benefits of their IT and telecom infrastructure while minimizing the use of their time and resources. “Tom,...

Continue reading

Talkspace Announces Fourth Quarter and Full Year 2024 Results

Full year 2024 total revenue grew 25% year-over-year to $187.6 millionFull year 2024 net income of $1.1 million and adjusted EBITDA1 of $7.0 million 4Q 2024 total revenue grew 15% year-over-year to $48.7 million4Q 2024 net income of $1.2 million and adjusted EBITDA1 of $2.7 million NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — Talkspace, Inc. (“Talkspace” or the “Company”) (NASDAQ: TALK), today reported fourth quarter and full year 2024 financial results.        Three Months Ended December 31, 2024   Year Ended December 31, 2024         Unaudited   Results   % Variance from Prior Year   Results   % Variance from Prior Year(In thousands unless otherwise noted)                Number of eligible lives at year end (in millions)   179.4   37%   179.4   37%Number of completed Payor sessions during the period   330.0   32%   1,229.2   45%Number...

Continue reading

Fairfax India Completes Acquisition of an Additional 10% Interest in Bangalore International Airport Limited

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this news release are expressed in U.S. dollars, except as otherwise noted). TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that, through its wholly-owned subsidiary, it has completed the acquisition of an additional 10% equity interest in Bangalore International Airport Limited (“BIAL”) from Siemens Project Ventures GmbH, part of Siemens Financial Services for, in aggregate, $255.0 million (the “Purchase Price”). As previously announced, the Purchase Price is payable in three installments, with the initial installment paid on closing of the transaction and the balance to be paid on August 31, 2025 and July 31, 2026. As a result...

Continue reading

Interim Management Report covering H1 2024/25

Interim Management Report covering H1 2024/25 The Board of Directors of Rovsing A/S has today approved the Interim Management Report for the first half-year (1 July 2024 – 31 December 2024) of the financial year 2024/25. Highlights of The Half YearThe first half year of 2024/25 has been a stabilization phase for Rovsing, maintaining the activity level at the same level as last year, when YoY revenue growth was 39%. In line with the strategy, the Company has explored opportunities for partnerships and expansion. This work has led to Rovsing entering into a new strategic cooperation agreement with Marble Imaging AG in November 2024, as well as plans to establish subsidiaries in two EU countries during H2, which will help ensure further growth in 2025/26.The order backlog at 31 December 2024 remains at a high level of DKK 34.9 million...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.